FIGURE 3.

Structures of CK2 inhibitors. (a) Emodin (6‐methyl‐1,3,8‐trihydroxyanthraquinone). (b) TBB (4,5,6,7‐tetrabromo‐2‐azabenzimidazole). (c) DRB (5,6‐dichlorobenzimidazole 1‐β‐D‐ribofuranoside). (d) Apigenin (4′,5,7‐trihydroxyflavone; 5,7‐dihydroxy‐2‐(4‐hydroxyphenyl)‐4H‐1‐benzopyran‐4‐one)